Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
J Med Econ
; 20(1): 8-18, 2017 Jan.
Article
in En
| MEDLINE
| ID: mdl-27472034
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Transplantation, Autologous
/
Hodgkin Disease
/
Cost-Benefit Analysis
/
Immunoconjugates
Type of study:
Guideline
/
Health_economic_evaluation
/
Health_technology_assessment
/
Observational_studies
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
J Med Econ
Journal subject:
SERVICOS DE SAUDE
Year:
2017
Document type:
Article
Affiliation country:
Reino Unido
Country of publication:
Reino Unido